The updated prescription information on Denosumab provides an overview of possible side effects, precautions, warnings, and storage tips. You'll also find brand names used in india and ...

Denosumab treatment for osteoporosis appears more hazardous in postmenopausal women with advanced chronic kidney disease (CKD).

The Food and Drug Administration (FDA) has added a new boxed warning on the denosumab drug label (brand name: Prolia) to alert clinicians to an increased risk for severe hypocalcemia in patients with ...

The risk for emergently treated hypocalcemia in individuals receiving denosumab peaked at 2 weeks after administration and ...

The phase 1/3 ROSALIA study showed that the copycat denosumab matched Amgen's brand on multiple pharmacokinetics, pharmacodynamics, efficacy, safety, and immunogenicity measures in postmenopausal ...

Amgen sells RANKL inhibitor denosumab as Prolia for osteoporosis ... have been approved for all of the indications of Amgen’s brands and, according to the company, are fully interchangeable ...